Lumida
/DNLI
⌘K
Denali Therapeutics Inc

Denali Therapeutics Inc

DNLI
$24.20USD-2.89%-0.72 today

MARKET CAP

3.9B

P/E (TTM)

FWD P/E

DAY RANGE

$23 – $25

52W RANGE

$13
$27

AI Summary

Stalk
StalkMedium

DNLI remains in a Stage 2 uptrend supported by a recently confirmed Bullish Pivot Point with rising EMAs, but the short-term rejection at the 9- and 20-day EMAs warrants patience, favoring deferred entries around the rising 50-day SMA or upon clear EMA acceptance for a higher-probability momentum continuation.

  • Q2 AVLAYAH revenue $3.6M; Q3 guidance $10–12M
  • Payer coverage secured for >50% of covered lives across 14 states
  • Q2 net loss $127.6M highlights ongoing unprofitability
Full analysis →
STATEMENT·Income statement
USD · GAAP
METRICFY 2019FY 2020FY 2021FY 2022FY 2023TREND
Sales, Adj.$26.7M$335.7M$48.7M$108.5M$330.5M
YoY %-79.3%+1158.2%-85.5%+122.9%+204.7%
P / Sales62.4x28.1x111.4x32.0x8.9x
EV / Sales65.4x28.0x114.4x33.8x8.9x
Gross Profit, Adj.$26.7M$335.7M$48.7M$108.5M$330.5M
YoY %-79.3%+1158.2%-85.5%+122.9%+204.7%
Margin %100.0%100.0%100.0%100.0%100.0%
EV / Gross Profit65.4x28.0x114.4x33.8x8.9x
EBITDA, Adj.$-205.2M$71.2M$-287.2M$-332.0M$-180.0M
YoY %-426.7%+134.7%-503.0%-15.6%+45.8%
Margin %-769.1%21.2%-590.1%-306.1%-54.4%
EV / EBITDA-8.5x131.7x-19.4x-11.0x-16.3x
EBIT$-213.2M$62.7M$-295.8M$-340.7M$-196.7M
YoY %-359.7%+129.4%-571.6%-15.2%+42.3%
Margin %-799.1%18.7%-607.8%-314.2%-59.5%
EV / EBIT-8.2x149.7x-18.8x-10.8x-14.9x
Net Income$-197.6M$71.1M$-290.6M$-326.0M$-145.2M
YoY %-445.3%+136.0%-508.5%-12.2%+55.5%
Net Margin-740.7%21.2%-597.2%-300.6%-43.9%
EPS (GAAP)-$2.07$0.63-$2.39-$2.60-$1.06
YoY %-430.8%+130.4%-479.4%-8.8%+59.2%